Indian Pharmaceutical Companies Launch Affordable Semaglutide After Patent Expiry
In a significant development for healthcare in India, several leading domestic pharmaceutical firms have announced the launch of semaglutide, a blockbuster weight-loss therapy, on the very first day following the expiration of its patent. This move is set to substantially lower the cost of treatment for millions of Indians struggling with obesity and related metabolic disorders.
Major Players Enter the Market
The companies spearheading this initiative include industry giants such as Sun Pharma, Torrent Pharmaceuticals, Zydus Lifesciences, Dr Reddy's Laboratories, Glenmark Pharmaceuticals, and Alkem Laboratories. Their entry into the market comes in the wake of innovator Novo Nordisk losing its patent on semaglutide on March 20, opening the door for more affordable generic versions.
Cost Reduction and Patient Support
Sun Pharma has revealed that its weekly therapy costs range from approximately Rs 900 to Rs 2,000 for Noveltreat and Rs 750 to Rs 1,300 for Sematrinity, making the treatment more accessible. Kirti Ganorkar, Managing Director of Sun Pharma, emphasized the company's commitment by stating, "To further support patients, we are also introducing a holistic patient support program intended to guide them throughout their treatment journey."
Expanding Treatment Options
Torrent Pharma has taken a pioneering step by launching both oral and injectable formulations of semaglutide, thereby expanding its presence in the metabolic disorders segment, which includes type-2 diabetes and obesity. Amal Kelshikar, CEO of India Business at Torrent Pharma, expressed pride in this achievement, saying, "We are proud to be the first Indian company to offer this treatment across oral and injectable formulations, giving healthcare professionals a holistic choice for treating patients."
Collaborative Efforts and Market Dynamics
Other companies, such as USV, have entered the market in collaboration with Dr Reddy's Labs. This flurry of launches reflects a broader strategic push by pharmaceutical companies to tap into India's rapidly expanding metabolic disorders market. Previously, blockbuster weight-loss therapies like Wegovy and Mounjaro, marketed by Novo Nordisk and Eli Lilly respectively, were launched at India-specific prices last year, while Ozempic by the Dutch firm made its debut in December.
Understanding Semaglutide
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that helps control blood sugar levels and improve satiety, thereby reducing food cravings and eventually inducing weight loss. Its introduction comes at a critical time as India faces an escalating diabetes burden, with over 100 million people currently living with the condition.
Implications for Healthcare
The launch of affordable semaglutide by Indian pharmaceutical companies is expected to revolutionize weight-loss therapy in the country, offering hope to many who previously found such treatments cost-prohibitive. This development underscores the growing capability of India's pharmaceutical sector to provide high-quality, cost-effective solutions for pressing health issues.
